Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic therapy for secondary and primary progressive multiple sclerosis.

L W Myers1

  • 1Multiple Sclerosis Research Center, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095-1769, USA. lmyers@ucla.edu

Current Neurology and Neuroscience Reports
|March 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebrospinal fluid immunoglobulin G promotes oligodendrocyte progenitor cell migration.

Journal of neuroscience research·2004
Same author

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2003
Same author

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.

Neurology·2002
Same author

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].

Neurology·2002
Same author

Factors related to agreement between self-reported and conventional Expanded Disability Status Scale (EDSS) scores.

Multiple sclerosis (Houndmills, Basingstoke, England)·2002
Same author

T-cell responses to oligodendrocyte-specific protein in multiple sclerosis.

Journal of neuroscience research·2001

Multiple sclerosis (MS) treatments target immune inflammation but do not halt progressive neurologic decline. Further research is crucial for effective progressive MS therapies, avoiding unproven regimens.

Area of Science:

  • Neuroimmunology
  • Neurology

Background:

  • Multiple sclerosis (MS) is an immune-mediated demyelinating disease.
  • MS commonly presents with a relapsing-remitting course, often progressing to secondary progressive MS.
  • Primary progressive MS involves gradual worsening from onset.

Purpose of the Study:

  • To review the current understanding of MS pathology, particularly axonal injury and neuronal degeneration in progressive MS.
  • To evaluate the efficacy of existing immunosuppressive and immunomodulatory treatments for progressive MS.
  • To highlight the need for rigorous clinical trials for new progressive MS therapies.

Main Methods:

  • Review of recent pathologic studies on MS.
  • Analysis of results from clinical trials of MS treatments.

Related Experiment Videos

  • Discussion of therapeutic approaches for progressive MS.

    • Main Results:

    • Axonal injury and neuronal degeneration are significant contributors to progressive neurologic decline in MS.
    • Current MS treatments effectively reduce relapse rates but do not stop disease progression.
    • No proven therapies currently exist to halt or reverse progressive MS.

    Conclusions:

    • Progressive neurologic decline in MS is linked to axonal damage, not just inflammation.
    • Effective treatments for progressive MS are lacking.
    • Well-designed clinical trials are essential to evaluate new therapies, while unproven treatments should be avoided.